Organigram Holdings Inc. (TSE:OGI - Free Report) - Analysts at Atb Cap Markets issued their Q4 2025 earnings per share (EPS) estimates for Organigram in a research note issued on Wednesday, December 18th. Atb Cap Markets analyst F. Gomes forecasts that the company will post earnings of ($0.01) per share for the quarter. The consensus estimate for Organigram's current full-year earnings is $0.16 per share.
A number of other equities research analysts have also commented on OGI. ATB Capital dropped their price objective on shares of Organigram from C$5.25 to C$3.50 in a report on Tuesday. Canaccord Genuity Group lowered their target price on Organigram from C$3.60 to C$3.15 and set a "speculative buy" rating for the company in a report on Monday, December 9th.
View Our Latest Report on OGI
Organigram Trading Up 6.2 %
TSE:OGI traded up C$0.13 on Friday, reaching C$2.22. The company's stock had a trading volume of 587,345 shares, compared to its average volume of 297,199. Organigram has a 1-year low of C$1.61 and a 1-year high of C$3.95. The business's 50-day moving average price is C$2.26 and its two-hundred day moving average price is C$2.30. The firm has a market cap of C$241.03 million, a PE ratio of -0.88, a PEG ratio of 0.42 and a beta of 1.13. The company has a debt-to-equity ratio of 1.13, a quick ratio of 2.62 and a current ratio of 6.95.
Insiders Place Their Bets
In related news, Senior Officer Paolo De Luca sold 12,014 shares of the company's stock in a transaction dated Thursday, October 24th. The shares were sold at an average price of C$2.52, for a total value of C$30,275.28. Company insiders own 31.32% of the company's stock.
Organigram Company Profile
(
Get Free Report)
Organigram Holdings Inc, through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co, Edison JOLTS, Tremblant, and Laurentian brands.
Read More
Before you consider Organigram, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Organigram wasn't on the list.
While Organigram currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
